Novartis: starts tender offer for AveXis
(CercleFinance.com) - Swiss drugmaker Novartis said on Tuesday that it has begun a tender offer to acquire all of AveXis' common stock for 218 dollars a share in cash.
The tender offer will expire at midnight on 14 May, unless extended.
Last week Novartis said it would buy the Nasdaq-listed company in a deal worth 8.7 billion dollars, giving it the right to a gene therapy which could be used to fight spinal muscular atrophy.
Novartis also said this Tuesday that it would invest 100 million dollars to research and develop next-generation antimalarials as part of its commitment to eliminate malaria.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The tender offer will expire at midnight on 14 May, unless extended.
Last week Novartis said it would buy the Nasdaq-listed company in a deal worth 8.7 billion dollars, giving it the right to a gene therapy which could be used to fight spinal muscular atrophy.
Novartis also said this Tuesday that it would invest 100 million dollars to research and develop next-generation antimalarials as part of its commitment to eliminate malaria.
Copyright (c) 2018 CercleFinance.com. All rights reserved.